tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF), Immatics (IMTX) and Pharvaris (PHVS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sanofi (SNYNFResearch Report), Immatics (IMTXResearch Report) and Pharvaris (PHVSResearch Report) with bullish sentiments.

Sanofi (SNYNF)

SVB Securities analyst David Risinger maintained a Buy rating on Sanofi on July 13 and set a price target of EUR121.00. The company’s shares closed last Friday at $102.34.

According to TipRanks.com, Risinger is a 2-star analyst with an average return of 2.1% and a 53.8% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Horizon Therapeutics, and Theravance Biopharma.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sanofi with a $117.33 average price target, representing a 14.6% upside. In a report issued on June 29, UBS also maintained a Buy rating on the stock with a EUR118.00 price target.

See today’s best-performing stocks on TipRanks >>

Immatics (IMTX)

SVB Securities analyst Jonathan Chang reiterated a Buy rating on Immatics on July 14 and set a price target of $17.00. The company’s shares closed last Friday at $8.62.

According to TipRanks.com, Chang has 0 stars on 0-5 stars ranking scale with an average return of -13.3% and a 27.2% success rate. Chang covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Karyopharm Therapeutics, and Bicycle Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Immatics with a $18.50 average price target.

Pharvaris (PHVS)

In a report issued on July 13, Joseph Schwartz from SVB Securities maintained a Buy rating on Pharvaris. The company’s shares closed last Friday at $23.10.

According to TipRanks.com, Schwartz is ranked 0 out of 5 stars with an average return of -8.6% and a 36.4% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Crinetics Pharmaceuticals, and Ultragenyx Pharmaceutical.

Pharvaris has an analyst consensus of Strong Buy, with a price target consensus of $40.67, implying a 74.2% upside from current levels. In a report issued on July 6, Oppenheimer also reiterated a Buy rating on the stock with a $48.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on SNYNF:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed